Zhongbang, established in 2001, has now become one of leading modern large-scale pharmaceutical manufacturing enterprises in China through over 15 years’ growth, specializing in the manufacture of APIs and intermediates integrating domestic & international sales with scientific research, industry and trade. Zhongbang is a wholly-owned subsidiary of Red Sun Group. With the registered capital of RMB 84 million, it covers a total area of 100,000 sq. m. and plans to have a total investment of RMB 200 million. Zhongbang got the first China GMP certificate in 2006, and renewed the qualification in 2015. The company also has the CEP certificate in EU since Jan, 2015. Zhongbang owns two GMP plants for APIs with four production lines and one GMP controlled plant for solid finished products.